Skip to main content
OpenTrials
Completed

NCT Number: NCT02487797

Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation

Oxytocin is a medication that is often used to strengthen contractions to overcome delayed labor progress. The primary aim of this study is to determine whether receiving a higher dose of oxytocin lowers the chance of needing a cesarean section when compared to a lower dose of oxytocin. Other aims include examining the relationship between dose of oxytocin regimen and length of labor, postpartum hemorrhage, intrauterine infection, umbilical cord gas, neonatal Apgar score <5 at 5 minutes, and need for neonatal intensive care.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States

About this study

This randomized double blind clinical trial of consenting nulliparous women in spontaneous labor who require oxytocin for labor augmentation seeks to determine whether use of a high dose oxytocin regimen improves obstetric outcomes when compared with a low dose oxytocin regimen, in a manner that is safe for both mother and neonate.

This project will include 1002 women recruited from the obstetrical service at Prentice Women's Hospital. Women will be included if they are at least 36 weeks gestation, have a singleton pregnancy, and have been diagnosed with spontaneous labor or spontaneous rupture of membranes. Women will be exposed to oxytocin for the indication of labor augmentation at the discretion of their obstetric provider.

Women will be randomized with equal probability to intervention group using a fixed allocation procedure. To maintain a double blind design, the Prentice Women's Hospital pharmacy will carry out the randomization of oxytocin solutions according to the random assignment so that neither the women or their care providers nor the investigators will know the identity of the intervention assignment. The low-dose oxytocin regimen group will receive a starting oxytocin regimen concentration rate of 2 milliunits/minute that can be increased at increments of 2 milliunits/minute, as per the discretion of their obstetric provider. The high-dose oxytocin regimen group will receive a starting oxytocin regimen concentration rate of 6 milliunits/minute that can be increased at increments of 6 milliunits/minute, as per the discretion of their obstetric provider.

Once the women are enrolled, randomized, and in receipt of their assigned interventions, further clinical management will be left to the discretion of each woman's obstetric provider.

Prior to discharge from the hospital, baseline demographic and clinical data will be obtained via chart review.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to give informed written consent
  • Age 18-45 years
  • Nulliparous
  • Pregnant with a live singleton gestation that is equal to or greater than 36 weeks
  • Diagnosed with at least 6 regular uterine contractions in an observation period of no more than 60 minutes and at least one of the following: spontaneous rupture of membranes, OR cervix greater than or equal to 3 centimeters dilated OR cervix at least 80% effaced.
  • The participant's attending obstetric physician or midwife has determined that the participant needs administration of oxytocin infusion for labor augmentation. Labor augmentation will be defined as stimulation of uterine contractions when spontaneous contractions have failed to result in progressive cervical dilation of descent of fetus.

Exclusion criteria

  • Women not meeting the above criteria
  • History of prior cesarean section or uterine surgery
  • Fetus in non-cephalic presentation
  • Participant is undergoing labor induction (i.e. cervical ripening)
  • Non-English speaking

Treatment and study plan

Oxytocin

Drug

Other names: Pitocin

Sodium Chloride 0.9%

Other

Other names: Normal Saline

Primary outcomes

  1. Number of Participants Delivered by Cesarean

    Time frame: At time of delivery

    Number of participants delivered by cesarean section

Secondary outcomes

  1. Labor Augmentation Duration

    Time frame: Number of hours from randomization to delivery

    Time from randomization to delivery

  2. Number of Participants With Postpartum Hemorrhage

    Time frame: From date of delivery to date of hospital discharge, an expected average of 3 days

    Estimated blood loss greater than 500 milliliters after a vaginal delivery or greater than 1000 milliliters after a cesarean delivery

  3. Number of Participants With Intrapartum Chorioamnionitis

    Time frame: From time of labor admission to time of delivery, an expected average of 24 to 48 hours

    Fever greater than 100.4 Fahrenheit in the intrapartum period with the initiation of a therapeutic antibiotic regimen in the intrapartum period

  4. Number of Participants With Postpartum Endometritis

    Time frame: From time of delivery to time of hospital discharge, an expected average of 3 days

    Fever greater than 100.4 Fahrenheit in the postpartum period with the initiation of a therapeutic antibiotic regimen in the postpartum period

  5. Number of Participants Whose Offspring Experiences a Perinatal Death

    Time frame: Study enrollment to delivery (if intrapartum stillbirth) or 28 days of life (if liveborn)

    Perinatal death includes intrapartum stillbirth and neonatal death

  6. Number of Participants With Umbilical Cord Acidemia

    Time frame: At time of delivery

    Umbilical cord arterial blood pH less than 7.0 or base deficit greater than 12 mmol/L; or cord venous blood pH less than 7.0 or base deficit greater than 12 mmol/L when umbilical artery values are not available

  7. Neonatal Apgar Score of Less Than 3 at 5 Minutes of Life

    Time frame: Delivery through 5 minutes of life

    Number of participants with neonates with Apgar score of less than 3 at 5 minutes of life. This is using a Apgar scale which ranges from minimum total score of 0 and maximum total score of 10, with higher score representing a better outcome.

  8. Admission to Neonatal Intensive Care Unit

    Time frame: Delivery to 28 days of life

    Number of participants whose neonates are admitted to Neonatal Intensive Care Unit

  9. Number of Participants Whose Neonates Experience a Composite of Severe Neonatal Morbidity and Perinatal Mortality

    Time frame: Delivery to 28 days of life

    Neonatal composite morbidity will be defined as occurrence of any of the following: perinatal death, severe, respiratory distress, major birth injury, encephalopathy, seizure, need for hypothermic treatment, or sepsis

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Registry information

Official study title

A Randomized Double Blind Clinical Trial Comparing Oxytocin Low-dose and High-dose Regimens for Labor Augmentation

Important dates

Study start
2015
Primary completion
2020
Study completion
2020
First posted
Jul 1, 2015
Registry last updated
Feb 11, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.